Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
InvisiShield Accelerates H5N1 & Pan-Influenza Intranasal Antibody
Details : InvisiShield accelerates its H5N1/Pan-influenza program to combat growing bird flu concerns. Their intranasal antibodies aim to prevent infection and disrupt transmission, offering a novel approach.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
January 28, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable